A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Leukemia, not otherwise specified | Leukemia, other | Myeloid and Monocytic Leukemia
What is the purpose of this trial?
The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care.
- Trial withActinium Pharmaceuticals, Inc.
- Start Date01/25/2021
- End Date12/31/2021
- Last Updated07/15/2021
- Study HIC#1607018056